ProtoKinetix, Incorporated (PKTX)
USD 0.01
(-16.79%)
USD 0.01
(-16.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -415.47 Thousand USD | 78.22% |
| 2022 | -1.9 Million USD | 18.12% |
| 2021 | -2.32 Million USD | 69.53% |
| 2020 | -7.64 Million USD | -82.1% |
| 2019 | -4.19 Million USD | -245.21% |
| 2018 | -1.21 Million USD | 19.57% |
| 2017 | -1.51 Million USD | 0.83% |
| 2016 | -1.52 Million USD | -21.19% |
| 2015 | -1.25 Million USD | -227.48% |
| 2014 | -384.17 Thousand USD | 9.0% |
| 2013 | -422.17 Thousand USD | -143.87% |
| 2012 | -173.11 Thousand USD | 80.87% |
| 2011 | -904.93 Thousand USD | 34.11% |
| 2010 | -1.37 Million USD | -10.22% |
| 2009 | -1.24 Million USD | 19.65% |
| 2008 | -1.55 Million USD | 42.91% |
| 2007 | -2.71 Million USD | -38.89% |
| 2006 | -1.95 Million USD | 59.37% |
| 2005 | -4.81 Million USD | 10.29% |
| 2004 | -5.36 Million USD | -253.59% |
| 2003 | -1.51 Million USD | -10098.58% |
| 2002 | -14.87 Thousand USD | 11.97% |
| 2001 | -16.9 Thousand USD | -48191.43% |
| 2000 | -35.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -85.08 Thousand USD | 7.56% |
| 2024 Q1 | -92.03 Thousand USD | 18.17% |
| 2023 Q2 | -115.57 Thousand USD | -7.98% |
| 2023 Q1 | -107.03 Thousand USD | 81.66% |
| 2023 FY | -415.48 Thousand USD | 78.22% |
| 2023 Q3 | -69.2 Thousand USD | 40.12% |
| 2023 Q4 | -112.47 Thousand USD | -62.52% |
| 2022 Q1 | -517.59 Thousand USD | -31.32% |
| 2022 Q2 | -442.15 Thousand USD | 14.57% |
| 2022 FY | -1.9 Million USD | 18.12% |
| 2022 Q4 | -583.65 Thousand USD | -57.73% |
| 2022 Q3 | -370.04 Thousand USD | 16.31% |
| 2021 FY | -2.32 Million USD | 69.53% |
| 2021 Q1 | -133.07 Thousand USD | 77.13% |
| 2021 Q2 | -403.73 Thousand USD | -203.39% |
| 2021 Q3 | -1.4 Million USD | -247.26% |
| 2021 Q4 | -394.15 Thousand USD | 71.89% |
| 2020 Q4 | -581.81 Thousand USD | 65.52% |
| 2020 Q3 | -1.68 Million USD | 23.5% |
| 2020 Q2 | -2.2 Million USD | 30.4% |
| 2020 Q1 | -3.16 Million USD | -29.13% |
| 2020 FY | -7.64 Million USD | -82.1% |
| 2019 Q2 | -769.25 Thousand USD | -101.15% |
| 2019 FY | -4.19 Million USD | -245.21% |
| 2019 Q1 | -382.43 Thousand USD | -94.69% |
| 2019 Q3 | -591.83 Thousand USD | 23.06% |
| 2019 Q4 | -2.45 Million USD | -314.7% |
| 2018 Q2 | -342.54 Thousand USD | -12.2% |
| 2018 Q1 | -305.28 Thousand USD | 40.17% |
| 2018 Q3 | -371.77 Thousand USD | -8.53% |
| 2018 Q4 | -196.43 Thousand USD | 47.16% |
| 2018 FY | -1.21 Million USD | 19.57% |
| 2017 Q3 | -299.19 Thousand USD | 8.54% |
| 2017 FY | -1.51 Million USD | 0.83% |
| 2017 Q1 | -375.38 Thousand USD | -0.17% |
| 2017 Q2 | -327.13 Thousand USD | 12.85% |
| 2017 Q4 | -510.26 Thousand USD | -70.55% |
| 2016 Q1 | -344.85 Thousand USD | 27.51% |
| 2016 Q2 | -370.78 Thousand USD | -7.52% |
| 2016 Q3 | -432.07 Thousand USD | -16.53% |
| 2016 Q4 | -374.74 Thousand USD | 13.27% |
| 2016 FY | -1.52 Million USD | -21.19% |
| 2015 Q1 | -257.3 Thousand USD | -38.9% |
| 2015 Q4 | -475.76 Thousand USD | -102.54% |
| 2015 Q3 | -234.9 Thousand USD | 19.04% |
| 2015 Q2 | -290.12 Thousand USD | -12.75% |
| 2015 FY | -1.25 Million USD | -227.48% |
| 2014 Q4 | -185.24 Thousand USD | -191.99% |
| 2014 Q3 | -63.44 Thousand USD | -6.18% |
| 2014 Q2 | -59.74 Thousand USD | 21.12% |
| 2014 Q1 | -75.74 Thousand USD | 52.31% |
| 2014 FY | -384.17 Thousand USD | 9.0% |
| 2013 FY | -422.17 Thousand USD | -143.87% |
| 2013 Q2 | -88.68 Thousand USD | -7.09% |
| 2013 Q4 | -158.81 Thousand USD | -72.88% |
| 2013 Q3 | -91.86 Thousand USD | -3.59% |
| 2013 Q1 | -82.81 Thousand USD | -94.62% |
| 2012 Q2 | -33.48 Thousand USD | 44.53% |
| 2012 Q3 | -38.22 Thousand USD | -14.17% |
| 2012 Q4 | -42.55 Thousand USD | -11.31% |
| 2012 FY | -173.11 Thousand USD | 80.87% |
| 2012 Q1 | -60.35 Thousand USD | 87.97% |
| 2011 Q2 | -186.65 Thousand USD | -60.91% |
| 2011 Q1 | -116 Thousand USD | 70.25% |
| 2011 Q3 | -100.4 Thousand USD | 46.21% |
| 2011 FY | -904.93 Thousand USD | 34.11% |
| 2011 Q4 | -501.87 Thousand USD | -399.85% |
| 2010 Q1 | -167.12 Thousand USD | 75.36% |
| 2010 Q3 | -582.78 Thousand USD | -188.02% |
| 2010 Q4 | -389.93 Thousand USD | 33.09% |
| 2010 FY | -1.37 Million USD | -10.22% |
| 2010 Q2 | -202.33 Thousand USD | -21.07% |
| 2009 Q1 | -122.88 Thousand USD | 26.51% |
| 2009 Q4 | -678.21 Thousand USD | -147.53% |
| 2009 Q3 | -273.98 Thousand USD | -60.21% |
| 2009 FY | -1.24 Million USD | 19.65% |
| 2009 Q2 | -171.02 Thousand USD | -39.17% |
| 2008 FY | -1.55 Million USD | 42.91% |
| 2008 Q3 | -429.51 Thousand USD | 29.51% |
| 2008 Q4 | -167.21 Thousand USD | 61.07% |
| 2008 Q2 | -609.32 Thousand USD | -83.1% |
| 2008 Q1 | -332.77 Thousand USD | 71.36% |
| 2007 Q1 | -286.36 Thousand USD | -291.63% |
| 2007 Q4 | -1.16 Million USD | -15.28% |
| 2007 Q3 | -1 Million USD | -287.3% |
| 2007 Q2 | -260.22 Thousand USD | 9.13% |
| 2007 FY | -2.71 Million USD | -38.89% |
| 2006 Q2 | -1.57 Million USD | -643.21% |
| 2006 Q1 | -212.58 Thousand USD | 76.9% |
| 2006 Q3 | -300.84 Thousand USD | 80.96% |
| 2006 Q4 | 149.44 Thousand USD | 149.67% |
| 2006 FY | -1.95 Million USD | 59.37% |
| 2005 Q3 | -66.52 Thousand USD | 98.12% |
| 2005 Q4 | -920.2 Thousand USD | -1283.18% |
| 2005 FY | -4.81 Million USD | 10.29% |
| 2005 Q2 | -3.53 Million USD | -1152.21% |
| 2005 Q1 | -282.37 Thousand USD | 91.72% |
| 2004 FY | -5.36 Million USD | -253.59% |
| 2004 Q3 | -222.71 Thousand USD | 67.31% |
| 2004 Q2 | -681.3 Thousand USD | 35.29% |
| 2004 Q1 | -1.05 Million USD | 15.56% |
| 2004 Q4 | -3.4 Million USD | -1430.38% |
| 2003 Q4 | -1.24 Million USD | -381.37% |
| 2003 Q3 | -259 Thousand USD | -7493.08% |
| 2003 FY | -1.51 Million USD | -10098.58% |
| 2003 Q2 | -3411.00 USD | 0.0% |
| 2002 FY | -14.87 Thousand USD | 11.97% |
| 2001 FY | -16.9 Thousand USD | -48191.43% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | -35.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 68.888% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 91.764% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 97.672% |
| Nascent Biotech, Inc. | -2.22 Million USD | 81.368% |
| Rebus Holdings, Inc. | -664 Thousand USD | 37.428% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.508% |
| Qrons Inc. | -643.67 Thousand USD | 35.452% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -6.651% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.251% |
| Skye Bioscience, Inc. | -13.67 Million USD | 96.961% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.421% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 108.454% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -58.746% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.452% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 85.424% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 72.951% |
| Mesoblast Limited | -84.14 Million USD | 99.506% |
| Marizyme, Inc. | -34.08 Million USD | 98.781% |
| Genus plc | 6.4 Million USD | 106.492% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 104.265% |
| Pharming Group N.V. | -4.87 Million USD | 91.485% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 79.085% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 55.391% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 95.024% |
| ContraFect Corporation | -56.88 Million USD | 99.27% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 90.878% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 70.365% |
| IMV Inc. | -38.67 Million USD | 98.926% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 84.896% |
| MultiCell Technologies, Inc. | -722.81 USD | -57381.081% |
| ONE Bio Corp. | 13.68 Million USD | 103.037% |
| Accustem Sciences Inc. | -3.74 Million USD | 88.91% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.296% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 13.991% |
| Q BioMed Inc. | -3.44 Million USD | 87.942% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 111.737% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 84.187% |
| Biomind Labs Inc. | -1 Million USD | 58.847% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.244% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 85.679% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 93.75% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 77.715% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1287.149% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 97.382% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 78.502% |
| GB Sciences, Inc. | -1.42 Million USD | 70.751% |
| Alpha Cognition Inc. | -9.7 Million USD | 95.719% |
| HST Global, Inc. | -140.9 Thousand USD | -194.86% |
| CSL Limited | 3.7 Billion USD | 100.011% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 63.065% |
| Halberd Corporation | -75.05 Thousand USD | -453.603% |
| Enzolytics Inc. | -2.14 Million USD | 80.665% |
| Agentix Corp. | -1.37 Million USD | 69.712% |
| Resverlogix Corp. | -12.74 Million USD | 96.741% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 86.886% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.902% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 60.203% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 85.769% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 73.693% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 87.798% |
| AVAX Technologies, Inc. | 6.69 Million USD | 106.208% |
| Zenith Capital Corp. | -8.94 Million USD | 95.354% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.9% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2284.932% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 83.078% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -142.248% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 79.275% |
| Kadimastem Ltd | -3.04 Million USD | 86.334% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 57.779% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 66.92% |
| BioStem Technologies, Inc. | -7.77 Million USD | 94.659% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -128.933% |
| LadRx Corporation | -3.82 Million USD | 89.134% |
| Cell Source, Inc. | -4.32 Million USD | 90.394% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 39.518% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 39.518% |
| NovAccess Global Inc. | -2.46 Million USD | 83.157% |
| Affymax, Inc. | -15.04 Million USD | 97.239% |
| Itoco Inc. | -919.14 Thousand USD | 54.797% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 90.197% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 62.871% |
| Mobile Lads Corp. | -554.55 Thousand USD | 25.078% |
| CytoDyn Inc. | -18.05 Million USD | 97.699% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1550.691% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -88.787% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 26.428% |
| SYBLEU INC | -149.18 Thousand USD | -178.509% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 77.125% |
| International Stem Cell Corporation | -663 Thousand USD | 37.333% |
| Bioxytran, Inc. | -3.82 Million USD | 89.124% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -689.284% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1942.67% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.854% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 74.321% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 43.536% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 86.645% |
| Neutra Corp. | -229.48 Thousand USD | -81.048% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 97.631% |
| PureTech Health plc | -146.19 Million USD | 99.716% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 98.067% |
| IXICO plc | -1.43 Million USD | 71.087% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 95.622% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.659% |
| CSL Limited | 3.81 Billion USD | 100.011% |
| Cellectis S.A. | -108.85 Million USD | 99.618% |